ophthalmology

News

Beacon debut sheds light on Syncona’s gene therapy plans

UK life sciences investor Syncona is bankrolling a new gene therapy company, Beacon Therapeutics, that emerged this morning with a pipeline headed by a therapy acquired fr

News

Astellas cuts $5.9bn deal to buy Iveric Bio

Astellas Pharma has agreed its largest-ever acquisition, buying US biotech Iveric Bio in a deal that continues to build its presence in the ophthalmology sector,

News

Vabysmo vaults into Roche’s top growth spot

The undisputed star of Roche’s pharma portfolio in the first quarter of this year is eye disease therapy Vabysmo, heading for blockbuster territory after posting sales of

News

Nanoscope gene therapy clears ph2 retinitis pigmentosa trial

Nanoscope Therapeutics has reported data from a mid-stage clinical trial that suggests its optogenetic therapy based on light-sensitive molecules is an effective treatment

News

Trials cue up new use for Roche's eye disease drug Vabysmo

Roche is on course for a third indication for its fast-growing ophthalmic disease therapy Vabysmo, after a pair of phase 3 trials showed it was effective at improving eyes

News